{"id":174,"date":"2025-03-04T14:16:29","date_gmt":"2025-03-04T14:16:29","guid":{"rendered":"https:\/\/euthanasiasleep.com\/?post_type=product&#038;p=174"},"modified":"2026-04-14T05:44:40","modified_gmt":"2026-04-14T05:44:40","slug":"nembutal-injectable-liquid","status":"publish","type":"product","link":"https:\/\/euthanasiasleep.com\/it\/prodotto\/nembutal-injectable-liquid\/","title":{"rendered":"Nembutal liquido iniettabile"},"content":{"rendered":"<div class=\"elementor-element elementor-element-4ef0951 wd-width-100 elementor-widget elementor-widget-wd_title\" data-id=\"4ef0951\" data-element_type=\"widget\" data-widget_type=\"wd_title.default\">\n<div class=\"elementor-widget-container\">\n<div class=\"title-wrapper wd-set-mb reset-last-child wd-title-color-primary wd-title-style-default wd-title-size-default text-left\">\n<div class=\"title-subtitle subtitle-color-primary subtitle-style-background wd-fontsize-xs\">\n<div class=\"elementor-element elementor-element-4ef0951 wd-width-100 elementor-widget elementor-widget-wd_title\" data-id=\"4ef0951\" data-element_type=\"widget\" data-widget_type=\"wd_title.default\">\n<div class=\"elementor-widget-container\">\n<div class=\"title-wrapper wd-set-mb reset-last-child wd-title-color-primary wd-title-style-default wd-title-size-default text-left\">\n<h2 class=\"title-subtitle subtitle-color-primary subtitle-style-background wd-fontsize-xs\"><strong>\u00a0Buy Liquid Injectable Nembutal Online<\/strong><\/h2>\n<div id=\"as0005\">\n<div id=\"sp0005\" class=\"u-margin-s-bottom\">Sodium pentobarbital (Nembutal) is a barbiturate used in research as an anesthetic in many animal models. The injectable form of this drug has lately become difficult to procure and prohibitively expensive. Due to this lack of availability, researchers have begun to compound injectable sodium pentobarbital from so-called \u201cnonpharmaceutical\u201d pentobarbital. Some oversight agencies have objected to this practice, claiming a lack of quality control and degradation of the drug. We sought with this study to establish both 1) a protocol for the preparation of injectable sodium pentobarbital and 2) standard operating procedures to monitor the quality of the preparation and degradation of the drug over time.<\/div>\n<\/div>\n<div id=\"as0010\">\n<h3 id=\"st0015\" class=\"u-h4 u-margin-m-top u-margin-xs-bottom\">Methods<\/h3>\n<div id=\"sp0010\" class=\"u-margin-s-bottom\">Our preparation consists of a mixture of sodium pentobarbital in alkaline aqueous solution,\u00a0<a class=\"topic-link\" title=\"Learn more about propylene glycol from ScienceDirect's AI-generated Topic Pages\" href=\"https:\/\/www.sciencedirect.com\/topics\/neuroscience\/propylene-glycol\">propylene glycol<\/a>, and ethanol. Pentobarbital content in this preparation was assayed by high-pressure liquid chromatography (HPLC). We also assayed pentobarbital content over time in preparations of various ages up to 6\u00a0years old.<\/div>\n<\/div>\n<div id=\"as0015\">\n<h3 id=\"st0020\" class=\"u-h4 u-margin-m-top u-margin-xs-bottom\">Results<\/h3>\n<div id=\"sp0015\" class=\"u-margin-s-bottom\">We determined that the drug degraded at a maximum of 0.5% per year in our preparation (alkaline water\/propylene glycol\/ethanol) when stored in the dark at room temperature. A yellow discoloration developed after about 2\u00a0years, which we have arbitrarily determined disqualifies the preparation from use as an anesthetic. Attempts to spectroscopically assay this discoloration were not successful.<\/div>\n<div><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div>\n<div id=\"preview-section-introduction\">\n<div class=\"Introduction u-font-serif u-margin-l-ver\">\n<section id=\"s0005\">\n<div id=\"p0005\" class=\"u-margin-s-bottom\">Compounds that exert sedative (reduce anxiety with no effect on motor function) or hypnotic (encourage a near-normal state of sleep) effects have been known since antiquity. These compounds have a variety of different chemistries; alcohols (ethanol), ethers (diethyl ether, paraldehyde), and various plant extracts (opium, cannabis, valerian) have all been used at various times as sedatives\/hypnotics. The use of barbiturates for this purpose began with the discovery in 1903 that barbital (diethylbarbituric acid) was effective at putting dogs to sleep (Fischer &amp; Von Mering, 1903). Bayer and Co. marketed barbital as veronal in 1904 for use as an anesthetic. By modifying the side chains and other ring substituents, other barbiturates have been developed which are longer- or shorter-acting, or have other specific properties related to anesthesia that make them desirable in specific circumstances [see (Lopez-Munoz, Ucha-Udabe, &amp; Alamo, 2005) for a review].<\/div>\n<div id=\"p0010\" class=\"u-margin-s-bottom\">Sodium pentobarbital was synthesized and introduced as an oral anesthetic by Abbott Laboratories in 1930. Injectable forms were introduced later, and there were even suppositories for use in children fearful of examination. The drug also enjoyed a period of popularity as a treatment for schizophrenia and anxiety. Today, sodium pentobarbital is used clinically as a pre-operative sedative, in certain forms of severe insomnia, and for the emergency management of seizures (Hobbs, Rall, &amp; Verdoorn, 1996).<\/div>\n<div id=\"p0015\" class=\"u-margin-s-bottom\">In research, pentobarbital is chiefly used as an anesthetic in many animal models. An overdose of pentobarbital produces severe CNS depression, which results in death (Trevor &amp; Way, 1982). In the research laboratory and veterinary clinic, pentobarbital is used in euthanasia as well as anesthesia. Indeed, until recently, pentobarbital was used in the execution of criminals in the United States, either alone or as part of a \u201clethal triad\u201d including pancuronium bromide and potassium chloride [see Zimmers et al.. (2007) or the Wikipedia entry <a class=\"anchor anchor-primary\" href=\"https:\/\/en.wikipedia.org\/wiki\/Pentobarbital\" target=\"_blank\" rel=\"noopener\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">http:\/\/en.wikipedia.org\/wiki\/Pentobarbital<\/span><\/span><\/a>\u00a0for a discussion of this use].<\/div>\n<div><\/div>\n<div id=\"p0020\" class=\"u-margin-s-bottom\">The clinical use of barbiturates has been largely supplanted by benzodiazepines for many reasons. These include a better therapeutic index (difference between a therapeutic and a lethal dose), lower risk of interactions with other drugs based on biotransformation, slow elimination rates, and lower addictive potential. This has led most manufacturers to discontinue making sodium pentobarbital. A single Danish supplier (Lundbeck) is now the sole approved source of injectable pentobarbital in the United States. Lack of availability has driven the price of a single 50 mL bottle of injectable pentobarbital to over $1000 US, a price which renders it \u201clogistically unavailable\u201d according to the National Institutes of Health (NIH).<\/div>\n<div><\/div>\n<div class=\"u-margin-s-bottom\">This agency has, therefore, allowed the use of \u201cnonpharmaceutical\u201d pentobarbital to prepare the injectable product with the approval of the Institutional Animal Care and Use Committee. Other oversight agencies that regularly inspect animal facilities [Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC), the United States Department of Agriculture (USDA)] have objected to this practice, claiming that the drug degrades over time and that quality control would suffer. While this might be true of sodium pentobarbital dissolved in water alone, we doubted that it was the case in solutions stabilized with propylene glycol.<\/div>\n<div id=\"p0025\" class=\"u-margin-s-bottom\">We decided, therefore, to establish procedures for 1) preparing the injectable pentobarbital, 2) assaying its concentration by methods (other than weight) available on-site, and 3) assessing the suitability of near-expired bottles for continued use, based on degradation of the drug. We also retained \u201cexpired\u201d bottles of the injectable pentobarbital for an assay of pentobarbital degradation over time. We found that our procedures created a safe, controlled environment for the use of this drug. We also found that, contrary to the concerns of inspecting agencies, the drug in our hands does not degrade substantially over time.<\/div>\n<\/section>\n<\/div>\n<\/div>\n<div class=\"hor-line-top u-padding-m-bottom u-padding-m-top u-text-center u-position-relative inserted-access-block\"><\/div>\n<\/div>\n<div class=\"elementor-widget-container\">\n<div class=\"title-wrapper wd-set-mb reset-last-child wd-title-color-primary wd-title-style-default wd-title-size-default text-left\">\n<div class=\"title-subtitle subtitle-color-primary subtitle-style-background wd-fontsize-xs\">\n<div class=\"elementor-element elementor-element-4ef0951 wd-width-100 elementor-widget elementor-widget-wd_title\" data-id=\"4ef0951\" data-element_type=\"widget\" data-widget_type=\"wd_title.default\">\n<div class=\"elementor-widget-container\">\n<div class=\"title-wrapper wd-set-mb reset-last-child wd-title-color-primary wd-title-style-default wd-title-size-default text-left\">\n<div id=\"as0020\"><\/div>\n<div class=\"title-after_title reset-last-child wd-fontsize-xs\">\n<p>If you\u2019re considering buying liquid Nembutal online, finding a reliable supplier is essential. Liquid Nembutal, also referred to as\u00a0<strong>Nembutal solution<\/strong>, is widely used in medical, veterinary, and research fields. At <a href=\"https:\/\/euthanasiasleep.com\/it\/\"  data-wpil-monitor-id=\"39\">Euthanasia<\/a> Sleep, we ensure high-quality products, secure transactions, and discreet shipping across Europe.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"elementor-element elementor-element-6bf0bfe wd-width-100 elementor-widget elementor-widget-wd_title\" data-id=\"6bf0bfe\" data-element_type=\"widget\" data-widget_type=\"wd_title.default\">\n<div class=\"elementor-widget-container\">\n<div class=\"title-wrapper wd-set-mb reset-last-child wd-title-color-primary wd-title-style-underlined wd-title-size-default text-left\">\n<div class=\"liner-continer\">\n<h5 class=\"woodmart-title-container title wd-fontsize-l\">What Is Liquid Nembutal?<\/h5>\n<\/div>\n<div class=\"title-after_title reset-last-child wd-fontsize-xs\">\n<p><a href=\"https:\/\/euthanasiasleep.com\/it\/tag-prodotto\/buy-nembutal-liquid-100mg-online\/\" data-wpil-monitor-id=\"16\">Liquid Nembutal injection <\/a>, also known as\u00a0<strong>sodium pentobarbital solution<\/strong>, is a barbiturate used for:<\/p>\n<ul>\n<li><strong>Medical Use:<\/strong>\u00a0Managing severe insomnia, seizures, or pre-surgical sedation.<\/li>\n<li><strong>Veterinary Use:<\/strong>\u00a0General anesthetic and humane euthanasia for animals.<\/li>\n<li><strong>Research Applications:<\/strong>\u00a0Ideal for laboratory pharmacological studies.<\/li>\n<\/ul>\n<p>Our liquid Nembutal is prepared under pharmaceutical-grade conditions, ensuring purity and reliability.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"elementor-element elementor-element-948a57d wd-width-100 elementor-widget elementor-widget-wd_title\" data-id=\"948a57d\" data-element_type=\"widget\" data-widget_type=\"wd_title.default\">\n<div class=\"elementor-widget-container\">\n<div class=\"title-wrapper wd-set-mb reset-last-child wd-title-color-primary wd-title-style-underlined wd-title-size-default text-left\">\n<div class=\"liner-continer\">\n<h5 class=\"woodmart-title-container title wd-fontsize-l\">Why Buy Nembutal Solution Online from Us?<\/h5>\n<\/div>\n<div class=\"title-after_title reset-last-child wd-fontsize-xs\">\n<p><strong>1. High-Quality Standards<\/strong><\/p>\n<p>We provide pharmaceutical-grade <a href=\"https:\/\/euthanasiasleep.com\/it\/tag-prodotto\/buy-nembutal-liquid\/\" data-wpil-monitor-id=\"6\">liquid Nembutal<\/a> solution, verified through rigorous lab testing to meet the highest standards of purity and effectiveness.<\/p>\n<p><strong>2. Secure and Discreet Transactions<\/strong><\/p>\n<ul>\n<li><strong>Confidential Shipping:<\/strong>\u00a0Every order is packed discreetly to protect your privacy.<\/li>\n<li><strong>Advanced Security:<\/strong>\u00a0Our platform uses robust encryption for safe online purchases.<\/li>\n<\/ul>\n<p><strong>3. Legal Compliance<\/strong><\/p>\n<p>We adhere to all EU regulations regarding the safe <a href=\"https:\/\/euthanasiasleep.com\/it\/tag-prodotto\/nembutal-liquid-for-sale\/\" data-wpil-monitor-id=\"5\">sale and delivery of liquid Nembutal<\/a>, ensuring you receive a product that is compliant with legal and safety standards. <a href=\"https:\/\/www.touteleurope.eu\/societe\/l-euthanasie-en-europe\/\">Click here<\/a>\u00a0to verify the EU regulations on Nembutal for your country.<\/p>\n<p><strong>4. Reliable Delivery<\/strong><\/p>\n<p>We specialize in secure and timely deliveries to EU countries, with tracking and customer support for every order.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"elementor-element elementor-element-fcec8ef wd-width-100 elementor-widget elementor-widget-wd_title\" data-id=\"fcec8ef\" data-element_type=\"widget\" data-widget_type=\"wd_title.default\">\n<div class=\"elementor-widget-container\">\n<div class=\"title-wrapper wd-set-mb reset-last-child wd-title-color-primary wd-title-style-underlined wd-title-size-default text-left\">\n<div class=\"liner-continer\">\n<h5 class=\"woodmart-title-container title wd-fontsize-l\">How to Use Liquid Nembutal Solution Safely<\/h5>\n<\/div>\n<div class=\"title-after_title reset-last-child wd-fontsize-xs\">\n<p>Proper handling and administration are essential for safe use:<\/p>\n<ul>\n<li><strong>Dosage Guidance:<\/strong>\u00a0Always consult a licensed professional to determine the correct dosage.<\/li>\n<li><strong>Storage Instructions:<\/strong>\u00a0Keep the solution in a cool, dry place, away from unauthorized access.<\/li>\n<li><strong>Legitimate Applications:<\/strong>\u00a0Ensure use is restricted to valid medical, veterinary, or research purposes.<\/li>\n<li>\n<div class=\"liner-continer\">\n<h5 class=\"woodmart-title-container title wd-fontsize-l\">Order Nembutal Solution Online Today<\/h5>\n<\/div>\n<div class=\"title-after_title reset-last-child wd-fontsize-xs\">\n<p>Take the hassle out of purchasing liquid Nembutal. At\u00a0<strong>Nembutal Mann<\/strong>, we combine premium quality, secure shopping, and reliable delivery to ensure your satisfaction.<\/p>\n<p><strong>Place your order now and experience seamless service from start to finish.<\/strong><\/p>\n<p>Looking for something else? You can\u00a0buy Nembutal tablets online\u00a0or\u00a0<a href=\"https:\/\/euthanasiasleep.com\/it\/prodotto\/nembutal-powder\/\" data-wpil-monitor-id=\"1\">buy Nembutal powder<\/a> online<\/p>\n<div class=\"DocumentTitle\">\n<p class=\"DocumentTitle\"><strong>NEMBUTAL SODIUM- pentobarbital sodium\u00a0injection\u00a0<\/strong><\/p>\n<\/div>\n<h1>Nembutal<span class=\"Sup\">\u00ae<\/span>\u00a0Sodium Solution CII<br \/>\n(pentobarbital sodium injection, USP)<\/h1>\n<div class=\"Contents\">\n<div class=\"Section\" data-sectioncode=\"34089-3\">\n<h1>DESCRIPTION<\/h1>\n<p class=\"First\">Barbiturates are nonselective central nervous system depressants that are primarily used as sedative hypnotics and also anticonvulsants in subhypnotic doses. Barbiturates and their sodium salts are subject to control under the Federal Controlled Substances Act (See \u201c<a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#s21\">Drug Abuse and Dependence<\/a>\u201d section).<\/p>\n<p>The sodium salts of amobarbital, pentobarbital, phenobarbital, and secobarbital are available as sterile parenteral solutions.<\/p>\n<p>Barbiturates are substituted pyrimidine derivatives in which the basic structure common to these drugs is barbituric acid, a substance which has no central nervous system (CNS) activity. CNS activity is obtained by substituting alkyl, alkenyl, or aryl groups on the pyrimidine ring.<\/p>\n<p>NEMBUTAL <a href=\"https:\/\/euthanasiasleep.com\/it\/prodotto\/nembutal-oral-solution\/\" data-wpil-monitor-id=\"21\">Sodium Solution<\/a> (pentobarbital sodium injection) is a sterile solution for intravenous or intramuscular injection. Each mL contains pentobarbital sodium 50 mg, in a vehicle of propylene glycol, 40%, alcohol, 10%, and water for injection, to volume. The pH is adjusted to approximately 9.5 with hydrochloric acid and\/or sodium hydroxide.<\/p>\n<p>NEMBUTAL Sodium is a short-acting barbiturate, chemically designated as sodium 5-ethyl-5-(1-methylbutyl) barbiturate. The structural formula for pentobarbital sodium is:<\/p>\n<div class=\"Figure\"><img decoding=\"async\" src=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/image.cfm?name=nem00-0009-01.jpg&amp;id=768556\" alt=\"Structural Formula \" \/><\/div>\n<p>The sodium salt occurs as a white, slightly bitter powder which is freely soluble in water and alcohol but practically insoluble in benzene and ether.<\/p>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"34090-1\">\n<h1>CLINICAL PHARMACOLOGY<\/h1>\n<p class=\"First\">Barbiturates are capable of producing all levels of CNS mood alteration from excitation to mild sedation, to hypnosis, and deep coma. Overdosage can produce death. In high enough therapeutic doses, barbiturates induce anesthesia.<\/p>\n<p>Barbiturates depress the sensory cortex, decrease motor activity, alter cerebellar function, and produce drowsiness, sedation, and hypnosis.<\/p>\n<p>Barbiturate-induced sleep differs from physiological sleep. Sleep laboratory studies have demonstrated that barbiturates reduce the amount of time spent in the rapid eye movement (REM) phase of sleep or the dreaming stage. Also, in Stages III and IV, sleep are decreased. Following abrupt cessation of barbiturates used regularly, patients may experience markedly increased dreaming, nightmares, and\/or insomnia. Therefore, withdrawal of a single therapeutic dose over 5 or 6 days has been recommended to lessen the REM rebound and disturbed sleep, which contribute to drug withdrawal syndrome (for example, decrease the dose from 3 to 2 doses a day for 1 week).<\/p>\n<p>In studies, secobarbital sodium and pentobarbital sodium have been found to lose most of their effectiveness for both inducing and maintaining sleep by the end of 2 weeks of continued drug administration at fixed doses. The short-, intermediate-, and, to a lesser degree, long-acting barbiturates have been widely prescribed for treating insomnia. Although the clinical literature abounds with claims that the short-acting barbiturates are superior for producing sleep while the intermediate-acting compounds are more effective in maintaining sleep, controlled studies have failed to demonstrate these differential effects. Therefore, as sleep medications, barbiturates are of limited value beyond short-term use.<\/p>\n<p>Barbiturates have little analgesic action at subanesthetic doses. Rather, in subanesthetic doses, these drugs may increase the reaction to painful stimuli. All barbiturates exhibit anticonvulsant activity in anesthetic doses. However, of the drugs in this class, only phenobarbital, mephobarbital, and metharbital have been clinically demonstrated to be effective as oral anticonvulsants in subhypnotic doses.<\/p>\n<p>Barbiturates are respiratory depressants. The degree of respiratory depression is dependent upon the dose. With hypnotic doses, respiratory depression produced by barbiturates is similar to that which occurs during physiologic sleep with slight decrease in blood pressure and heart rate.<\/p>\n<p>Studies in laboratory animals have shown that barbiturates cause a reduction in the tone and contractility of the uterus, ureters, and urinary bladder. However, concentrations of the drugs required to produce this effect in humans are not reached with sedative\/hypnotic doses.<\/p>\n<p>Barbiturates do not impair normal hepatic function but have been shown to induce liver microsomal enzymes, thus increasing and\/or altering the metabolism of barbiturates and other drugs. (See \u201c<span class=\"Italics\"><a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#s13\">Precautions-Drug Interactions<\/a><\/span>\u201d section).<\/p>\n<div class=\"Section\" data-sectioncode=\"43682-4\">\n<h2>Pharmacokinetics:<\/h2>\n<p class=\"First\">Barbiturates are absorbed in varying degrees following oral, rectal, or parenteral administration. The salts are more rapidly absorbed than the acids.<\/p>\n<p>The onset of action for oral or rectal administration varies from 20 to 60 minutes. For IM administration, the onset of action is slightly faster. Following IV administration, the onset of action ranges from almost immediately for pentobarbital sodium to 5 minutes for phenobarbital sodium. Maximal CNS depression may not occur until 15 minutes or more after IV administration for phenobarbital sodium.<\/p>\n<p>Duration of action, which is related to the rate at which the barbiturates are redistributed throughout the body, varies among persons and in the same person from time to time.<\/p>\n<p>No studies have demonstrated that the different routes of administration are equivalent for bioavailability.<\/p>\n<p>Barbiturates are weak acids that are absorbed and rapidly distributed to all tissues and fluids with high concentrations in the brain, liver, and kidneys. The lipid solubility of the barbiturates is the dominant factor in their distribution within the body. The more lipid soluble the barbiturate, the more rapidly it penetrates all tissues of the body. Barbiturates are bound to plasma and tissue proteins to a varying degree, with the degree of binding increasing directly as a function of lipid solubility.<\/p>\n<p>Phenobarbital has the lowest lipid solubility, lowest plasma binding, lowest brain protein binding, the longest delay in onset of activity, and the longest duration of action. At the opposite extreme is secobarbita,l which has the highest lipid solubility, plasma protein binding, and brain protein binding, the shortest delay in onset of activity, and the shortest duration of action. Butabarbital is classified as an intermediate barbiturate.<\/p>\n<p>The plasma half-life for pentobarbital in adults is 15 to 50 hours and appears to be dose-dependent.<\/p>\n<p>Barbiturates are metabolized primarily by the hepatic microsomal enzyme system, and the metabolic products are excreted in the urine and, less commonly, in the feces. Approximately 25 to 50 percent of a dose of aprobarbital or phenobarbital is eliminated unchanged in the urine, whereas the amount of other barbiturates excreted unchanged in the urine is negligible. The excretion of unmetabolized barbiturate is one feature that distinguishes the long-acting category from those belonging to other categories, which are almost entirely metabolized. The inactive metabolites of the barbiturates are excreted as conjugates of glucuronic acid.<\/p>\n<\/div>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"34067-9\">\n<h1>INDICATIONS AND USAGE<\/h1>\n<div class=\"Section\" data-sectioncode=\"42229-5\">\n<h2>Parenteral:<\/h2>\n<ol class=\"LittleAlpha\">\n<li>Sedatives.<\/li>\n<li>Hypnotics, for the short-term treatment of insomnia, since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks (See \u201c<a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#s3\">Clinical Pharmacology<\/a>\u201d section.)<\/li>\n<li>Preanesthetics.<\/li>\n<li>Anticonvulsant, in anesthetic doses, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics.<\/li>\n<\/ol>\n<\/div>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"34070-3\">\n<h1>CONTRAINDICATIONS<\/h1>\n<p class=\"First\">Barbiturates are contraindicated in patients with known barbiturate sensitivity. Barbiturates are also contraindicated in patients with a history of manifest or latent porphyria.<\/p>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"34071-1\">\n<h1>WARNINGS<\/h1>\n<ol class=\"Arabic\">\n<li><span class=\"Italics\">Habit-forming<\/span>: Barbiturates may be habit-forming. Tolerance and psychological and physical dependence may occur with continued use. (See \u201c<a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#s21\">Drug Abuse and Dependence<\/a>\u201d and \u201c<span class=\"Italics\"><a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#s4\">Pharmacokinetics<\/a><\/span>\u201d sections.) Patients who have psychological dependence on barbiturates may increase the dosage or decrease the dosage interval without consulting a physician and may subsequently develop a physical dependence on barbiturates. To minimize the possibility of overdosage or the development of dependence, the prescribing and dispensing of sedative-hypnotic barbiturates should be limited to the amount required for the interval until the next appointment. Abrupt cessation after prolonged use in the dependent person may result in withdrawal symptoms, including delirium, convulsions, and possibly death. Barbiturates should be withdrawn gradually from any patient known to be taking excessive dosage over long periods of time. (See \u201c<a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#s21\">Drug Abuse and Dependence<\/a>\u201d section.)<\/li>\n<li><span class=\"Italics\">IV administration:<\/span> Too rapid an administration may cause respiratory depression, apnea, laryngospasm, or vasodilation with a fall in blood pressure.<\/li>\n<li><span class=\"Italics\">Acute or chronic pain:<\/span> Caution should be exercised when barbiturates are administered to patients with acute or chronic pain because paradoxical excitement could be induced, or important symptoms could be masked. However, the use of barbiturates as sedatives in the postoperative surgical period and as adjuncts to cancer chemotherapy is well established.<\/li>\n<li>\n<p class=\"First\"><span class=\"Italics\">Use in pregnancy:<\/span> Barbiturates can cause fetal damage when administered to a pregnant woman. Retrospective, case-controlled studies have suggested a connection between the maternal consumption of barbiturates and a higher-than-expected incidence of fetal abnormalities. Following oral or parenteral administration, barbiturates readily cross the placental barrier and are distributed throughout fetal tissues, with the highest concentrations found in the placenta, fetal liver, and brain. Fetal blood levels approach maternal blood levels following parenteral administration.<\/p>\n<p>Withdrawal symptoms occur in infants born to mothers who receive barbiturates throughout the last trimester of pregnancy. (See \u201c<a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#s21\">Drug Abuse and Dependence<\/a>\u201d section.) If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.<\/li>\n<li><span class=\"Italics\">Synergistic effects:<\/span>\u00a0The concomitant use of alcohol or other CNS depressants may produce additive CNS depressant effects.<\/li>\n<li>\n<p class=\"First\"><span class=\"Italics\">Pediatric neurotoxicity:<\/span>\u00a0Published animal studies demonstrate that the administration of anesthetic and sedation drugs that block NMDA receptors and\/or potentiate GABA activity increase neuronal apoptosis in the developing brain and result in long-term cognitive deficits when used for longer than 3 hours. The clinical significance of these findings is not clear. However, based on the available data, the window of vulnerability to these changes is believed to correlate with exposures in the third trimester of gestation through the first several months of life, but may extend out to approximately three years of age in humans (see \u201c<span class=\"Italics\"><a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#s15\">Precautions-Pregnancy<\/a><\/span>\u00a0and\u00a0<span class=\"Italics\"><a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#s18\">Pediatric Use<\/a><\/span>\u201d and \u201c<a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#s30\">Animal Pharmacology and\/or Toxicology<\/a>\u201d).<\/p>\n<p>Some published studies in children suggest that similar deficits may occur after repeated or prolonged exposures to anesthetic agents early in life and may result in adverse cognitive or behavioral effects. These studies have substantial limitations, and it is not clear if the observed effects are due to the anesthetic\/sedation drug administration or other factors such as the surgery or underlying illness.<\/p>\n<p>Anesthetic and sedation drugs are a necessary part of the care of children and pregnant women needing surgery, other procedures, or tests that cannot be delayed, and no specific medications have been shown to be safer than any other. Decisions regarding the timing of any elective procedures requiring anesthesia should take into consideration the benefits of the procedure weighed against the potential risks.<\/li>\n<\/ol>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"42232-9\">\n<h1>PRECAUTIONS<\/h1>\n<div class=\"Section\" data-sectioncode=\"34072-9\">\n<h2>General:<\/h2>\n<p class=\"First\">Barbiturates may be habit-forming. Tolerance and psychological and physical dependence may occur with continued use. (See \u201c<a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#s21\">Drug Abuse and Dependence<\/a>\u201d section.) Barbiturates should be administered with caution, if at all, to patients who are mentally depressed, have suicidal tendencies, or have a history of drug abuse.<\/p>\n<p>Elderly or debilitated patients may react to barbiturates with marked excitement, depression, and confusion. In some persons, barbiturates repeatedly produce excitement rather than depression.<\/p>\n<p>In patients with hepatic damage, barbiturates should be administered with caution and initially in reduced doses. Barbiturates should not be administered to patients showing the premonitory signs of hepatic coma.<\/p>\n<p>Parenteral solutions of barbiturates are highly alkaline. Therefore, extreme care should be taken to avoid perivascular extravasation or intra-arterial injection. Extravascular injection may cause local tissue damage with subsequent necrosis; consequences of intra-arterial injection may vary from transient pain to gangrene of the limb. Any complaint of pain in the limb warrants stopping the injection.<\/p>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"34076-0\">\n<h2>Information for the patient:<\/h2>\n<p class=\"First\">Practitioners should give the following information and instructions to patients receiving barbiturates.<\/p>\n<ol class=\"Arabic\">\n<li>The use of barbiturates carries with it an associated risk of psychological and\/or physical dependence. The patient should be warned against increasing the dose of the drug without consulting a physician.<\/li>\n<li>Barbiturates may impair mental and\/or physical abilities required for the performance of potentially hazardous tasks (e.g., driving, operating machinery, etc.).<\/li>\n<li>Alcohol should not be consumed while taking barbiturates. Concurrent use of the barbiturates with other CNS depressants (e.g., alcohol, narcotics, tranquilizers, and antihistamines) may result in additional CNS depressant effects.<\/li>\n<li><span class=\"Bold\">Effect of anesthetic and sedation drugs on early brain development<br \/>\n<\/span>Studies conducted in young animals and children suggest that repeated or prolonged use of general anesthetic or sedation drugs in children younger than 3 years may have negative effects on their developing brains. Discuss with parents and caregivers the benefits, risks, and timing and duration of surgery or procedures requiring anesthetic and sedation drugs. Because some animal data suggest that the window of vulnerability includes the 3rd trimester of pregnancy, discuss with pregnant women the benefits, risks, and timing and duration of surgery or procedures requiring anesthetic and sedation drugs. (See \u201c<span class=\"Italics\"><a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#p01\">Warnings-Pediatric Neurotoxicity<\/a><\/span>\u201d.)<\/li>\n<\/ol>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"34075-2\">\n<h2>Laboratory tests:<\/h2>\n<p class=\"First\">Prolonged therapy with barbiturates should be accompanied by periodic laboratory evaluation of organ systems, including hematopoietic, renal, and hepatic systems. (See the \u201c<span class=\"Italics\"><a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#s10\">Precautions-General<\/a><\/span>\u201d and \u201c<a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#s20\">Adverse Reactions<\/a>\u201d sections.)<\/p>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"34073-7\">\n<h2>Drug interactions:<\/h2>\n<p class=\"First\">Most reports of clinically significant drug interactions occurring with the barbiturates have involved phenobarbital. However, the application of these data to other barbiturates appears valid and warrants serial blood level determinations of the relevant drugs when there are multiple therapies.<\/p>\n<ol class=\"Arabic\">\n<li><span class=\"Italics\">Anticoagulants<\/span>: Phenobarbital lowers the plasma levels of dicumarol (name previously used: bishydroxycoumarin) and causes a decrease in anticoagulant activity as measured by the prothrombin time. Barbiturates can induce hepatic microsomal enzymes, resulting in increased metabolism and decreased anticoagulant response of oral anticoagulants (e.g., warfarin, acenocoumarol, dicumarol, and phenprocoumon). Patients stabilized on anticoagulant therapy may require dosage adjustments if barbiturates are added to or withdrawn from their dosage regimen.<\/li>\n<li><span class=\"Italics\">Corticosteroids<\/span>: Barbiturates appear to enhance the metabolism of exogenous corticosteroid,s probably through the induction of hepatic microsomal enzymes. Patients stabilized on corticosteroid therapy may require dosage adjustments if barbiturates are added to or withdrawn from their dosage regimen.<\/li>\n<li><span class=\"Italics\">Griseofulvin<\/span>: Phenobarbital appears to interfere with the absorption of orally administered griseofulvin, thus decreasing its blood level. The effect of the resultant decreased blood levels of griseofulvin on therapeutic response has not been established. However, it would be preferable to avoid concomitant administration of these drugs.<\/li>\n<li><span class=\"Italics\">Doxycycline<\/span>: Phenobarbital has been shown to shorten the half-life of doxycycline for as long as 2 weeks after barbiturate therapy is discontinued.<br \/>\nThis mechanism is probably through the induction of hepatic microsomal enzymes that metabolize the antibiotic. If phenobarbital and doxycycline are administered concurrently, the clinical response to doxycycline should be monitored closely.<\/li>\n<li><span class=\"Italics\">Phenytoin, sodium valproate, valproic acid:<\/span> The effect of barbiturates on the metabolism of phenytoin appears to be variable. Some investigators report an accelerating effect, while others report no effect. Because the effect of barbiturates on the metabolism of phenytoin is not predictable, phenytoin and barbiturate blood levels should be monitored more frequently if these drugs are given concurrently. Sodium valproate and valproic acid appear to decrease barbiturate metabolism; therefore, barbiturate blood levels should be monitored, and appropriate dosage adjustments made as indicated.<\/li>\n<li><span class=\"Italics\">Central nervous system depressants:<\/span>\u00a0The concomitant use of other central nervous system depressants, including other sedatives or hypnotics, antihistamines, tranquilizers, or alcohol, may produce additive depressant effects.<\/li>\n<li><span class=\"Italics\">Monoamine oxidase inhibitors (MAOI):<\/span> MAOI prolong the effects of barbiturates, probably because the metabolism of the barbiturate is inhibited.<\/li>\n<li><span class=\"Italics\">Estradiol, estrone, progesterone, and other steroidal hormones:<\/span>\u00a0Pretreatment with or concurrent administration of phenobarbital may decrease the effect of estradiol by increasing its metabolism. There have been reports of patients treated with antiepileptic drugs (e.g., phenobarbital) who became pregnant while taking oral contraceptives. An alternate contraceptive method might be suggested to women taking phenobarbital.<\/li>\n<\/ol>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"34083-6\">\n<h2>Carcinogenesis:<\/h2>\n<ol class=\"Arabic\">\n<li><span class=\"Italics\">Animal data.<\/span>\u00a0Phenobarbital sodium is carcinogenic in mice and rats after lifetime administration. In mice, it produced benign and malignant liver cell tumors. In rats, benign liver cell tumors were observed very late in life.<\/li>\n<li><span class=\"Italics\">Human data.<\/span>\u00a0In a 29-year epidemiological study of 9,136 patients who were treated on an anticonvulsant protocol that included phenobarbital, results indicated a higher than normal incidence of hepatic carcinoma. Previously, some of these patients were treated with thorotrast, a drug that is known to produce hepatic carcinomas. Thus, this study did not provide sufficient evidence that phenobarbital sodium is carcinogenic in humans.<br \/>\nData from one retrospective study of 235 children in which the types of barbiturates are not identified suggested an association between exposure to barbiturates and an increased incidence of brain tumors. (Gold, E., et al., \u201cIncreased Risk of Brain Tumors in Children Exposed to Barbiturates,\u201d Journal of National Cancer Institute, 61:1031-1034, 1978).<\/li>\n<\/ol>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"42228-7\">\n<h2>Pregnancy:<\/h2>\n<ol class=\"Arabic\">\n<li><span class=\"Italics\">Teratogenic effects.<\/span>\u00a0Pregnancy Category D\u2014See \u201c<span class=\"Italics\"><a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#p02\">Warnings-Use in Pregnancy<\/a><\/span>\u201d section.<\/li>\n<li><span class=\"Italics\">Nonteratogenic effects.<\/span>\u00a0Reports of infants suffering from long-term barbiturate exposure\u00a0<span class=\"Italics\">in utero<\/span>\u00a0included the acute withdrawal syndrome of seizures and hyperirritability from birth to a delayed onset of up to 14 days. (See \u201c<a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#s21\">Drug Abuse and Dependence<\/a>\u201d section.)<\/li>\n<li>Published studies in pregnant primates demonstrate that the administration of anesthetic and sedation drugs that block NMDA receptors and\/or potentiate GABA activity during the period of peak brain development increases neuronal apoptosis in the developing brain of the offspring when used for longer than 3 hours. There are no data on pregnancy exposures in primates corresponding to periods before the third trimester in humans.\n<p class=\"First\">In a published study, administration of an anesthetic dose of ketamine for 24 hours on Gestation Day 122 increased neuronal apoptosis in the developing brain of the fetus. In other published studies, the administration of either isoflurane or propofol for 5 hours on Gestation Day 120 resulted in increased neuronal and oligodendrocyte apoptosis in the developing brain of the offspring. For brain development, this period corresponds to the third trimester of gestation in humans. The clinical significance of these findings is not clear; however, studies in juvenile animals suggest neuroapoptosis correlates with long-term cognitive deficits (see \u201c<span class=\"Italics\"><a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#p01\">Warnings-Pediatric Neurotoxicity<\/a><\/span>\u201d, \u201c<span class=\"Italics\"><a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#s18\">Precautions-Pediatric Use<\/a><\/span>\u201d, and \u201c<a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#s30\">Animal Pharmacology and\/or Toxicology<\/a>\u201d).<\/p>\n<\/li>\n<\/ol>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"34079-4\">\n<h2>Labor and delivery:<\/h2>\n<p class=\"First\">Hypnotic doses of these barbiturates do not appear to impair uterine activity significantly during labor. Full anesthetic doses of barbiturates decrease the force and frequency of uterine contractions. The administration of sedative-hypnotic barbiturates to the mother during labor may result in respiratory depression in the newborn. Premature infants are particularly susceptible to the depressant effects of barbiturates. If barbiturates are used during labor and delivery, resuscitation equipment should be available.<\/p>\n<p>Data are currently not available to evaluate the effect of these barbiturates when forceps delivery or other intervention is necessary. Also, data are not available to determine the effect of these barbiturates on the later growth, development, and functional maturation of the child.<\/p>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"34080-2\">\n<h2>Nursing mothers:<\/h2>\n<p class=\"First\">Caution should be exercised when a barbiturate is administered to a nursing woman since small amounts of barbiturates are excreted in the milk.<\/p>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"34081-0\">\n<h2>Pediatric use:<\/h2>\n<p class=\"First\">No adequate well-controlled studies have been conducted in pediatric patients; however, safety and effectiveness of pentobarbital in pediatric patients is supported by numerous studies and case reports cited in the literature.<\/p>\n<p>Pediatric dosing information for Nembutal is described in the\u00a0<a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#s23\">DOSAGE AND ADMINISTRATION<\/a>\u00a0section.<\/p>\n<p>Published juvenile animal studies demonstrate that the administration of anesthetic and sedation drugs, such as Pentobarbital Sodium Injection USP, (Nembutal) that either block NMDA receptors or potentiate the activity of GABA during the period of rapid brain growth or synaptogenesis, results in widespread neuronal and oligodendrocyte cell loss in the developing brain and alterations in synaptic morphology and neurogenesis. Based on comparisons across species, the window of vulnerability to these changes is believed to correlate with exposures in the third trimester of gestation through the first several months of life, but may extend out to approximately 3 years of age in humans.<\/p>\n<p>In primates, exposure to 3 hours of ketamine that produced a light surgical plane of anesthesia did not increase neuronal cell loss, however, treatment regimens of 5 hours or longer of isoflurane increased neuronal cell loss. Data from isoflurane-treated rodents and ketamine-treated primates suggest that the neuronal and oligodendrocyte cell losses are associated with prolonged cognitive deficits in learning and memory. The clinical significance of these nonclinical findings is not known, and healthcare providers should balance the benefits of appropriate anesthesia in pregnant women, neonates, and young children who require procedures with the potential risks suggested by the nonclinical data (see \u201c<span class=\"Italics\"><a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#p01\">Warnings-Pediatric Neurotoxicity<\/a><\/span>\u201d, \u201c<span class=\"Italics\"><a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#s15\">Precautions-Pregnancy<\/a><\/span>\u201d, and \u201c<a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#s30\">Animal Pharmacology and\/or Toxicology<\/a>\u201d.)<\/p>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"34082-8\">\n<h2>Geriatric use:<\/h2>\n<p class=\"First\">Clinical studies of Nembutal have not included sufficient numbers of subjects aged 65 and over to determine whether elderly subjects respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.<\/p>\n<p>Elderly patients may react to barbiturates with marked excitement, depression, and confusion. In some persons, barbiturates repeatedly produce excitement rather than depression. Dosage should be reduced in the elderly because these patients may be more sensitive to barbiturates.<\/p>\n<\/div>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"34084-4\">\n<h1>ADVERSE REACTIONS<\/h1>\n<p class=\"First\">The following adverse reactions and their incidence were compiled from the surveillance of thousands of hospitalized patients. Because such patients may be less aware of certain of the milder adverse effects of barbiturates, the incidence of these reactions may be somewhat higher in fully ambulatory patients.<\/p>\n<p><span class=\"Italics\">More than 1 in 100 patients.<\/span>\u00a0The most common adverse reaction estimated to occur at a rate of 1 to 3 patients per 100 is:\u00a0<span class=\"Italics\">Nervous System:<\/span>\u00a0Somnolence.<\/p>\n<p><span class=\"Italics\">Less than 1 in 100 patients.<\/span> Adverse reactions estimated to occur at a rate of less than 1 in 100 patients listed below, grouped by organ system and by decreasing order of occurrence are:<\/p>\n<p><span class=\"Italics\">Nervous system:<\/span> Agitation, confusion, hyperkinesia, ataxia, CNS depression, nightmares, nervousness, psychiatric disturbance, hallucinations, insomnia, anxiety, dizziness, and thinking abnormality.<\/p>\n<p><span class=\"Italics\">Respiratory system:<\/span>\u00a0Hypoventilation, apnea.<\/p>\n<p><span class=\"Italics\">Cardiovascular system:<\/span>\u00a0Bradycardia, hypotension, syncope.<\/p>\n<p><span class=\"Italics\">Digestive system:<\/span>\u00a0Nausea, vomiting, constipation.<\/p>\n<p><span class=\"Italics\">Other reported reactions:<\/span> Headache, injection site reactions, hypersensitivity reactions (angioedema, skin rashes, exfoliative dermatitis), fever, liver damage, and megaloblastic anemia following chronic phenobarbital use.<\/p>\n<p><span class=\"Bold\">To report SUSPECTED ADVERSE REACTIONS, contact Oak Pharmaceuticals, Inc. at 1-800-932-5676 or FDA at 1-800-FDA-1088 or www.fda.gov\/medwatch.<\/span><\/p>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"42227-9\">\n<h1>DRUG ABUSE AND DEPENDENCE<\/h1>\n<p class=\"First\">Pentobarbital sodium injection is subject to control by the Federal Controlled Substances Act under DEA schedule II.<\/p>\n<p>Barbiturates may be habit-forming. Tolerance, psychological dependence, and physical dependence may occur, especially following prolonged use of high doses of barbiturates. Daily administration of over 400 milligrams (mg) of pentobarbital or secobarbital for approximately 90 days is likely to produce some degree of physical dependence. A dosage of 600 to 800 mg taken for at least 35 days is sufficient to produce withdrawal seizures. The average daily dose for the barbiturate addict is usually about 1.5 grams. As tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fatal dosage, however, does not increase more than twofold. As this occurs, the margin between an intoxicating dosage and a fatal dosage becomes smaller.<\/p>\n<p>Symptoms of acute intoxication with barbiturates include unsteady gait, slurred speech, and sustained nystagmus. Mental signs of chronic intoxication include confusion, poor judgment, irritability, insomnia, and somatic complaints.<\/p>\n<p>Symptoms of barbiturate dependence are similar to those of chronic alcoholism. If an individual appears to be intoxicated with alcohol to a degree that is radically disproportionate to the amount of alcohol in his or her blood, the use of barbiturates should be suspected. The <a href=\"https:\/\/euthanasiasleep.com\/it\/tag-prodotto\/nembutal-liquid-lethal-dose\/\" data-wpil-monitor-id=\"2\">lethal dose<\/a> of a barbiturate is far less if alcohol is also ingested.<\/p>\n<p>The symptoms of barbiturate withdrawal can be severe and may cause death. Minor withdrawal symptoms may appear 8 to 12 hours after the last dose of a barbiturate. These symptoms usually appear in the following order: anxiety, muscle twitching, tremor of hands and fingers, progressive weakness, dizziness, distortion in visual perception, nausea, vomiting, insomnia, and orthostatic hypotension. Major withdrawal symptoms (convulsions and delirium) may occur within 16 hours and last up to 5 days after abrupt cessation of these drugs. The intensity of withdrawal symptoms gradually declines over approximately 15 days. Individuals susceptible to barbiturate abuse and dependence include alcoholics and opiate abusers, as well as other sedative-hypnotic and amphetamine abusers.<\/p>\n<p>Drug dependence to barbiturates arises from repeated administration of a barbiturate or agent with a barbiturate-like effect continuously, generally in amounts exceeding therapeutic dose levels. The characteristics of drug dependence to barbiturates include: (a) a strong desire or need to continue taking the drug; (b) a tendency to increase the dose; (c) a psychic dependence on the effects of the drug related to subjective and individual appreciation of those effects; and (d) a physical dependence on the effects of the drug requiring its presence for maintenance of homeostasis and resulting in a definite, characteristic, and self-limited abstinence syndrome when the drug is withdrawn.<\/p>\n<p>Treatment of barbiturate dependence consists of cautious and gradual withdrawal of the drug. Barbiturate-dependent patients can be withdrawn by using a number of different withdrawal regimens. In all cases withdrawal takes an extended period of time. One method involves substituting a 30 mg dose of phenobarbital for each 100 to 200 mg dose of barbiturate that the patient has been taking. The total daily amount of phenobarbital is then administered in 3 to 4 divided doses, not to exceed 600 mg daily. Should signs of withdrawal occur on the first day of treatment, a loading dose of 100 to 200 mg of phenobarbital may be administered IM in addition to the oral dose. After stabilization on phenobarbital, the total daily dose is decreased by 30 mg a day as long as withdrawal is proceeding smoothly. A modification of this regimen involves initiating treatment at the patient&#8217;s regular dosage level and decreasing the daily dosage by 10 percent if tolerated by the patient.<\/p>\n<p>Infants physically dependent on barbiturates may be given phenobarbital 3 to 10 mg\/kg\/day. After withdrawal symptoms (hyperactivity, disturbed sleep, tremors, hyperreflexia) are relieved, the dosage of phenobarbital should be gradually decreased and completely withdrawn over 2 weeks.<\/p>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"34088-5\">\n<h1>OVERDOSAGE<\/h1>\n<p class=\"First\">The toxic dose of barbiturates varies considerably. In general, an oral dose of 1 gram of most barbiturates produces serious poisoning in an adult. Death commonly occurs after 2 to 10 grams of ingested barbiturate. Barbiturate intoxication may be confused with alcoholism, bromide intoxication, and various neurological disorders.<\/p>\n<p>Acute overdosage with barbiturates is manifested by CNS and respiratory depression, which may progress to Cheyne-Stokes respiration, areflexia, constriction of the pupils to a slight degree (though in severe poisoning they may show paralytic dilation), oliguria, tachycardia, hypotension, lowered body temperature, and coma. Typical shock syndrome (apnea, circulatory collapse, respiratory arrest, and death) may occur.<\/p>\n<p>In extreme overdose, all electrical activity in the brain may cease, in which case a \u201cflat\u201d EEG normally equated with clinical death cannot be accepted. This effect is fully reversible unless hypoxic damage occurs. Consideration should be given to the possibility of barbiturate intoxication even in situations that appear to involve trauma.<\/p>\n<p>Complications such as pneumonia, pulmonary edema, cardiac arrhythmias, congestive heart failure, and renal failure may occur. Uremia may increase CNS sensitivity to barbiturates. Differential diagnosis should include hypoglycemia, head trauma, cerebrovascular accidents, convulsive states, and diabetic coma. Blood levels from acute overdosage for some barbiturates are listed in\u00a0<a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#t1\">Table 1<\/a>.<\/p>\n<table class=\"Noautorules\" width=\"100%\">\n<caption>Table 1. Concentration of Barbiturate in the Blood Versus Degree of CNS Depression<\/caption>\n<colgroup>\n<col width=\"17.591%\" align=\"left\" \/>\n<col width=\"18.320%\" align=\"left\" \/>\n<col width=\"12.818%\" align=\"left\" \/>\n<col width=\"12.818%\" align=\"left\" \/>\n<col width=\"12.818%\" align=\"left\" \/>\n<col width=\"12.818%\" align=\"left\" \/>\n<col width=\"12.818%\" align=\"left\" \/><\/colgroup>\n<tfoot>\n<tr>\n<td colspan=\"7\" align=\"left\" valign=\"top\">\n<p class=\"First Footnote\">* Categories of degree of depression in nontolerant persons:<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"7\" align=\"left\" valign=\"top\">\n<p class=\"First Footnote\">1. Under the influence and appreciably impaired for purposes of driving a motor vehicle or performing tasks requiring alertness and unimpaired judgment and reaction time.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"7\" align=\"left\" valign=\"top\">\n<p class=\"First Footnote\">2. Sedated, therapeutic range, calm, relaxed, and easily aroused.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"7\" align=\"left\" valign=\"top\">\n<p class=\"First Footnote\">3. Comatose, difficult to arouse, significant depression of respiration.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"7\" align=\"left\" valign=\"top\">\n<p class=\"First Footnote\">4. Compatible with death in aged or ill persons or in the presence of obstructed airway, other toxic agents, or exposure to cold.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"7\" align=\"left\" valign=\"top\">\n<p class=\"First Footnote\">5. Usual lethal level, the upper end of the range includes those who received some supportive treatment.<\/p>\n<\/td>\n<\/tr>\n<\/tfoot>\n<tbody class=\"Headless\">\n<tr>\n<td class=\"Botrule\" colspan=\"7\" align=\"center\" valign=\"middle\">Blood barbiturate level in ppm (\u03bcg\/mL)<\/td>\n<\/tr>\n<tr>\n<td class=\"Botrule\" rowspan=\"2\" align=\"left\" valign=\"middle\">Barbiturate<\/td>\n<td class=\"Botrule\" rowspan=\"2\" align=\"left\" valign=\"middle\">Onset\/duration<\/td>\n<td colspan=\"5\" align=\"center\" valign=\"middle\"><span class=\"Underline\">Degree of depression in nontolerant persons*<\/span><\/td>\n<\/tr>\n<tr>\n<td class=\"Botrule\" align=\"center\" valign=\"top\">1<\/td>\n<td class=\"Botrule\" align=\"center\" valign=\"top\">2<\/td>\n<td class=\"Botrule\" align=\"center\" valign=\"top\">3<\/td>\n<td class=\"Botrule\" align=\"center\" valign=\"top\">4<\/td>\n<td class=\"Botrule\" align=\"center\" valign=\"top\">5<\/td>\n<\/tr>\n<tr>\n<td align=\"justify\" valign=\"top\">Pentobarbital<\/td>\n<td align=\"justify\" valign=\"top\">Fast\/short<\/td>\n<td align=\"center\" valign=\"top\">\u22642<\/td>\n<td align=\"center\" valign=\"top\">0.5 to 3<\/td>\n<td align=\"center\" valign=\"top\">10 to 15<\/td>\n<td align=\"center\" valign=\"top\">12 to 25<\/td>\n<td align=\"center\" valign=\"top\">15 to 40<\/td>\n<\/tr>\n<tr>\n<td align=\"justify\" valign=\"top\">Secobarbital<\/td>\n<td align=\"justify\" valign=\"top\">Fast\/short<\/td>\n<td align=\"center\" valign=\"top\">\u22642<\/td>\n<td align=\"center\" valign=\"top\">0.5 to 5<\/td>\n<td align=\"center\" valign=\"top\">10 to 15<\/td>\n<td align=\"center\" valign=\"top\">15 to 25<\/td>\n<td align=\"center\" valign=\"top\">15 to 40<\/td>\n<\/tr>\n<tr>\n<td align=\"justify\" valign=\"top\">Amobarbital<\/td>\n<td align=\"justify\" valign=\"top\">Intermediate\/<br \/>\nintermediate<\/td>\n<td align=\"center\" valign=\"top\">\u22643<\/td>\n<td align=\"center\" valign=\"top\">2 to 10<\/td>\n<td align=\"center\" valign=\"top\">30 to 40<\/td>\n<td align=\"center\" valign=\"top\">30 to 60<\/td>\n<td align=\"center\" valign=\"top\">40 to 80<\/td>\n<\/tr>\n<tr>\n<td align=\"justify\" valign=\"top\">Butabarbital<\/td>\n<td align=\"justify\" valign=\"top\">Intermediate\/<br \/>\nintermediate<\/td>\n<td align=\"center\" valign=\"top\">\u22645<\/td>\n<td align=\"center\" valign=\"top\">3 to 25<\/td>\n<td align=\"center\" valign=\"top\">40 to 60<\/td>\n<td align=\"center\" valign=\"top\">50 to 80<\/td>\n<td align=\"center\" valign=\"top\">60 to 100<\/td>\n<\/tr>\n<tr>\n<td class=\"Botrule\" align=\"justify\" valign=\"top\">Phenobarbital<\/td>\n<td class=\"Botrule\" align=\"justify\" valign=\"top\">Slow\/long<\/td>\n<td class=\"Botrule\" align=\"center\" valign=\"top\">\u226410<\/td>\n<td class=\"Botrule\" align=\"center\" valign=\"top\">5 to 40<\/td>\n<td class=\"Botrule\" align=\"center\" valign=\"top\">50 to 80<\/td>\n<td class=\"Botrule\" align=\"center\" valign=\"top\">70 to 120<\/td>\n<td class=\"Botrule\" align=\"center\" valign=\"top\">100 to 200<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Treatment of overdosage is mainly supportive and consists of the following:<\/p>\n<ol class=\"Arabic\">\n<li>Maintenance of an adequate airway, with assisted respiration and oxygen administration as necessary.<\/li>\n<li>Monitoring of vital signs and fluid balance.<\/li>\n<li>Fluid therapy and other standard treatment for shock, if needed.<\/li>\n<li>If renal function is normal, forced diuresis may aid in the elimination of the barbiturate. Alkalinization of the urine increases renal excretion of some barbiturates, especially phenobarbital, as well as aprobarbital and mephobarbital (which is metabolized to phenobarbital).<\/li>\n<li>Although not recommended as a routine procedure, hemodialysis may be used in severe barbiturate intoxications or if the patient is anuric or in shock.<\/li>\n<li>Patient should be rolled from side to side every 30 minutes.<\/li>\n<li>Antibiotics should be given if pneumonia is suspected.<\/li>\n<li>Appropriate nursing care to prevent hypostatic pneumonia, decubiti, aspiration, and other complications of patients with altered states of consciousness.<\/li>\n<\/ol>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"34068-7\">\n<h1>DOSAGE AND ADMINISTRATION<\/h1>\n<p class=\"First\">Dosages of barbiturates must be individualized with full knowledge of their particular characteristics and recommended rate of administration. Factors of consideration are the patient&#8217;s age, weight, and condition. Parenteral routes should be used only when oral administration is impossible or impractical.<\/p>\n<div class=\"Section\" data-sectioncode=\"42229-5\">\n<p class=\"First\"><span class=\"Italics\">Intramuscular Administration:<\/span>\u00a0IM injection of the sodium salts of barbiturates should be made deeply into a large muscle, and a volume of 5 mL should not be exceeded at any one site because of possible tissue irritation. After IM injection of a hypnotic dose, the patient&#8217;s vital signs should be monitored. The usual adult dosage of NEMBUTAL Sodium Solution is 150 to 200 mg as a single IM injection; the recommended pediatric dosage ranges from 2 to 6 mg\/kg as a single IM injection not to exceed 100 mg.<\/p>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"42229-5\">\n<p class=\"First\"><span class=\"Italics\">Intravenous Administration:<\/span>\u00a0NEMBUTAL Sodium Solution should not be admixed with any other medication or solution. IV injection is restricted to conditions in which other routes are not feasible, either because the patient is unconscious (as in cerebral hemorrhage, eclampsia, or status epilepticus), or because the patient resists (as in delirium), or because prompt action is imperative. Slow IV injection is essential, and patients should be carefully observed during administration. This requires that blood pressure, respiration, and cardiac function be maintained, vital signs be recorded, and equipment for resuscitation and artificial ventilation be available. The rate of IV injection should not exceed 50 mg\/min for pentobarbital sodium.<\/p>\n<p>There is no average intravenous dose of NEMBUTAL Sodium Solution (pentobarbital sodium injection) that can be relied on to produce similar effects in different patients. The possibility of overdose and respiratory depression is remote when the drug is injected slowly in fractional doses.<\/p>\n<p>A commonly used initial <a href=\"https:\/\/euthanasiasleep.com\/it\/tag-prodotto\/pentobarbital-dose-for-adults\/\"  data-wpil-monitor-id=\"40\">dose for the 70 kg adult<\/a> is 100 mg. Proportional reduction in dosage should be made for pediatric or debilitated patients. At least one minute is necessary to determine the full effect of intravenous pentobarbital. If necessary, additional small increments of the drug may be given up to a total of from 200 to 500 mg for normal adults.<\/p>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"42229-5\">\n<p class=\"First\"><span class=\"Italics\">Anticonvulsant use:<\/span>\u00a0In convulsive states, dosage of NEMBUTAL Sodium Solution should be kept to a minimum to avoid compounding the depression which may follow convulsions. The injection must be made slowly with due regard to the time required for the drug to penetrate the blood-brain barrier.<\/p>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"42229-5\">\n<p class=\"First\"><span class=\"Italics\">Special patient population:<\/span>\u00a0Dosage should be reduced in the elderly or debilitated because these patients may be more sensitive to barbiturates. Dosage should be reduced for patients with impaired renal function or hepatic disease.<\/p>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"42229-5\">\n<p class=\"First\"><span class=\"Italics\">Inspection:<\/span> Parenteral drug products should be inspected visually for particulate matter and discoloration priorto administration, whenever solution containers permit. Solutions for injection showing evidence of precipitation should not be used.<\/p>\n<\/div>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"34069-5\">\n<h1>HOW SUPPLIED<\/h1>\n<p class=\"First\">NEMBUTAL Sodium Solution (pentobarbital sodium injection, USP) is available in the following sizes:<\/p>\n<p>20-mL multiple-dose vial, 1 g per vial (NDC 76478-501-20); and 50-mL multiple-dose vial, 2.5\u00a0g per vial (NDC 76478-501-50).<\/p>\n<p>Each mL contains:<\/p>\n<p>Pentobarbital Sodium, derivative of barbituric acid \u2026\u2026\u2026\u2026\u2026\u2026.. 50 mg<br \/>\nPropylene glycol \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 \u00a040% v\/v<br \/>\nAlcohol \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.. 10%<br \/>\nWater for Injection \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026. qs<\/p>\n<p>(pH adjusted to approximately 9.5 with hydrochloric acid and\/or sodium hydroxide.)<\/p>\n<p>Vial stoppers are latex-free.<\/p>\n<p>Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. It is recommended that the product be stored at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); however, brief excursions are permitted between 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F). See USP controlled room temperature.<\/p>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"34091-9\">\n<h1>ANIMAL PHARMACOLOGY AND\/OR TOXICOLOGY<\/h1>\n<p class=\"First\">Published studies in animals demonstrate that the use of anesthetic agents during the period of rapid brain growth or synaptogenesis results in widespread neuronal and oligodendrocyte cell loss in the developing brain and alterations in synaptic morphology and neurogenesis. Based on comparisons across species, the window of vulnerability to these changes is believed to correlate with exposures in the third trimester through the first several months of life but may extend out to approximately 3 years of age in humans.<\/p>\n<p>In primates, 3 hours of exposure to an anesthetic regimen that produced a light surgical plane of anesthesia did not increase neuronal cell loss; however, treatment regimens of 5 hours or longer increased neuronal cell loss. Data in rodents and in primates suggest that the neuronal and oligodendrocyte cell losses are associated with subtle but prolonged cognitive deficits in learning and memory. The clinical significance of these nonclinical findings is not known, and healthcare providers should balance the benefits of appropriate anesthesia in neonates and young children who require procedures against the potential risks suggested by the nonclinical data (see \u201c<span class=\"Italics\"><a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#p01\">Warnings-Pediatric Neurotoxicity<\/a><\/span>\u201d and \u201c<span class=\"Italics\"><a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#s15\">Precautions-Pregnancy<\/a><\/span>\u00a0and\u00a0<span class=\"Italics\"><a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=5c380ab0-4386-48b6-80ab-ca594b23bc74#s18\">Pediatric Use<\/a><\/span>\u201d).<\/p>\n<p>AKORN<br \/>\nDistributed by:<br \/>\n<span class=\"Bold\">Akorn Operating Company LLC<\/span><br \/>\nGurnee, IL 60031<\/p>\n<p>OPNM00N\u00a0 \u00a0 \u00a0 \u00a0 \u00a0Rev. 03\/22<\/p>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"51945-4\">\n<p class=\"First\">Principal Display Panel Text for Container Label:<\/p>\n<p>NDC 76478-501-20 20 mL Sterile Solution<\/p>\n<p>Nembutal<span class=\"Sup\">\u00ae<\/span><\/p>\n<p>Sodium Solution<\/p>\n<p>(pentobarbital sodium injection, USP)<\/p>\n<p>50 mg\/mL\u00a0<span class=\"Bold\">CII<\/span><\/p>\n<p>For Intravenous or Intramuscular Use.<\/p>\n<p>Multiple-dose Vial. LATEX-FREE<\/p>\n<p>Rx only Akorn logo<\/p>\n<div class=\"Figure\"><img decoding=\"async\" src=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/image.cfm?name=nem00-0009-02.jpg&amp;id=768556\" alt=\"Principal Display Panel Text for Container Label \" \/><\/div>\n<\/div>\n<div class=\"Section\" data-sectioncode=\"51945-4\">\n<p>NDC 76478-501-20 20 mL<\/p>\n<p>Sterile Solution<\/p>\n<p>Nembutal<span class=\"Sup\">\u00ae<\/span><\/p>\n<p>Sodium Solution<\/p>\n<p>(pentobarbital sodium<\/p>\n<p>injection, USP)<\/p>\n<p>50 mg\/mL\u00a0<span class=\"Bold\">CII<\/span><\/p>\n<p>For Intravenous or Intramuscular Use.<\/p>\n<p>Multiple-dose Vial. LATEX-FREE.<\/p>\n<p>Caution: This solution is not suitable<\/p>\n<p>for subcutaneous administration.<\/p>\n<div class=\"Figure\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>&nbsp;<\/p>\n<p>If you are looking to buy liquid Nembutal online, contact our representative on WhatsApp or email US for your Nembutal. Our pharmaceutical-grade Nembutal solution offers unmatched quality, reliability, and secure delivery across Europe, the USA, and Asia. Ideal for medical, veterinary, and research applications, this product adheres to strict EU and US regulations for your peace of mind. Order now for a seamless and discreet shopping experience!<\/p>","protected":false},"featured_media":214,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[19],"product_cat":[18],"product_tag":[24,20,25,23,21,22,27,26],"class_list":{"0":"post-174","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_brand-pentobarbital-sodium","7":"product_cat-nembutal","8":"product_tag-buy-nembutal-liquid","9":"product_tag-buy-nembutal-liquid-100mg-online","10":"product_tag-buy-nembutal-liquid-online","11":"product_tag-nembutal-liquid","12":"product_tag-nembutal-liquid-for-sale","13":"product_tag-nembutal-liquid-lethal-dose","14":"product_tag-order-nembutal-liquid-online","15":"product_tag-where-to-buy-nembutal-liquid","17":"first","18":"instock","19":"shipping-taxable","20":"purchasable","21":"product-type-simple"},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.2 (Yoast SEO v26.2) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Nembutal Injectable liquid - euthanasiasleep.com<\/title>\n<meta name=\"description\" content=\"Buy Nembutal Injectable liquid for Euthanasia while understanding the procedure of administration and preparation for human use at Euthanasia sleep\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/euthanasiasleep.com\/it\/prodotto\/nembutal-injectable-liquid\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nembutal Injectable liquid\" \/>\n<meta property=\"og:description\" content=\"Buy Nembutal Injectable liquid for Euthanasia while understanding the procedure of administration and preparation for human use at Euthanasia sleep\" \/>\n<meta property=\"og:url\" content=\"https:\/\/euthanasiasleep.com\/it\/prodotto\/nembutal-injectable-liquid\/\" \/>\n<meta property=\"og:site_name\" content=\"euthanasiasleep.com\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-14T05:44:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/euthanasiasleep.com\/wp-content\/uploads\/2025\/03\/5927197908527072606.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data1\" content=\"31 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/euthanasiasleep.com\/product\/nembutal-injectable-liquid\/\",\"url\":\"https:\/\/euthanasiasleep.com\/product\/nembutal-injectable-liquid\/\",\"name\":\"Nembutal Injectable liquid - euthanasiasleep.com\",\"isPartOf\":{\"@id\":\"https:\/\/euthanasiasleep.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/euthanasiasleep.com\/product\/nembutal-injectable-liquid\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/euthanasiasleep.com\/product\/nembutal-injectable-liquid\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/euthanasiasleep.com\/wp-content\/uploads\/2025\/03\/5927197908527072606.jpg\",\"datePublished\":\"2025-03-04T14:16:29+00:00\",\"dateModified\":\"2026-04-14T05:44:40+00:00\",\"description\":\"Buy Nembutal Injectable liquid for Euthanasia while understanding the procedure of administration and preparation for human use at Euthanasia sleep\",\"breadcrumb\":{\"@id\":\"https:\/\/euthanasiasleep.com\/product\/nembutal-injectable-liquid\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/euthanasiasleep.com\/product\/nembutal-injectable-liquid\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/euthanasiasleep.com\/product\/nembutal-injectable-liquid\/#primaryimage\",\"url\":\"https:\/\/euthanasiasleep.com\/wp-content\/uploads\/2025\/03\/5927197908527072606.jpg\",\"contentUrl\":\"https:\/\/euthanasiasleep.com\/wp-content\/uploads\/2025\/03\/5927197908527072606.jpg\",\"width\":1280,\"height\":960,\"caption\":\"Numbutal injectable solution from Euthanasia sleep\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/euthanasiasleep.com\/product\/nembutal-injectable-liquid\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/euthanasiasleep.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shop\",\"item\":\"https:\/\/euthanasiasleep.com\/shop\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nembutal Injectable liquid\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/euthanasiasleep.com\/#website\",\"url\":\"https:\/\/euthanasiasleep.com\/\",\"name\":\"Euthanasia Sleep\",\"description\":\"Euthanasia Sleep\",\"publisher\":{\"@id\":\"https:\/\/euthanasiasleep.com\/#organization\"},\"alternateName\":\"EuthanasiaSleep\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/euthanasiasleep.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/euthanasiasleep.com\/#organization\",\"name\":\"Euthanasia Sleep\",\"alternateName\":\"EuthanasiaSleep\",\"url\":\"https:\/\/euthanasiasleep.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/euthanasiasleep.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/euthanasiasleep.com\/wp-content\/uploads\/2025\/03\/kisspng-health-care-public-health-medicine-hospital-cupped-hands-5b5bed5c4cf652.0198420915327511963153.jpg\",\"contentUrl\":\"https:\/\/euthanasiasleep.com\/wp-content\/uploads\/2025\/03\/kisspng-health-care-public-health-medicine-hospital-cupped-hands-5b5bed5c4cf652.0198420915327511963153.jpg\",\"width\":900,\"height\":800,\"caption\":\"Euthanasia Sleep\"},\"image\":{\"@id\":\"https:\/\/euthanasiasleep.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Nembutal Injectable liquid - euthanasiasleep.com","description":"Buy Nembutal Injectable liquid for Euthanasia while understanding the procedure of administration and preparation for human use at Euthanasia sleep","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/euthanasiasleep.com\/it\/prodotto\/nembutal-injectable-liquid\/","og_locale":"it_IT","og_type":"article","og_title":"Nembutal Injectable liquid","og_description":"Buy Nembutal Injectable liquid for Euthanasia while understanding the procedure of administration and preparation for human use at Euthanasia sleep","og_url":"https:\/\/euthanasiasleep.com\/it\/prodotto\/nembutal-injectable-liquid\/","og_site_name":"euthanasiasleep.com","article_modified_time":"2026-04-14T05:44:40+00:00","og_image":[{"width":1280,"height":960,"url":"https:\/\/euthanasiasleep.com\/wp-content\/uploads\/2025\/03\/5927197908527072606.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Tempo di lettura stimato":"31 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/euthanasiasleep.com\/product\/nembutal-injectable-liquid\/","url":"https:\/\/euthanasiasleep.com\/product\/nembutal-injectable-liquid\/","name":"Nembutal Injectable liquid - euthanasiasleep.com","isPartOf":{"@id":"https:\/\/euthanasiasleep.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/euthanasiasleep.com\/product\/nembutal-injectable-liquid\/#primaryimage"},"image":{"@id":"https:\/\/euthanasiasleep.com\/product\/nembutal-injectable-liquid\/#primaryimage"},"thumbnailUrl":"https:\/\/euthanasiasleep.com\/wp-content\/uploads\/2025\/03\/5927197908527072606.jpg","datePublished":"2025-03-04T14:16:29+00:00","dateModified":"2026-04-14T05:44:40+00:00","description":"Buy Nembutal Injectable liquid for Euthanasia while understanding the procedure of administration and preparation for human use at Euthanasia sleep","breadcrumb":{"@id":"https:\/\/euthanasiasleep.com\/product\/nembutal-injectable-liquid\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/euthanasiasleep.com\/product\/nembutal-injectable-liquid\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/euthanasiasleep.com\/product\/nembutal-injectable-liquid\/#primaryimage","url":"https:\/\/euthanasiasleep.com\/wp-content\/uploads\/2025\/03\/5927197908527072606.jpg","contentUrl":"https:\/\/euthanasiasleep.com\/wp-content\/uploads\/2025\/03\/5927197908527072606.jpg","width":1280,"height":960,"caption":"Numbutal injectable solution from Euthanasia sleep"},{"@type":"BreadcrumbList","@id":"https:\/\/euthanasiasleep.com\/product\/nembutal-injectable-liquid\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/euthanasiasleep.com\/"},{"@type":"ListItem","position":2,"name":"Shop","item":"https:\/\/euthanasiasleep.com\/shop\/"},{"@type":"ListItem","position":3,"name":"Nembutal Injectable liquid"}]},{"@type":"WebSite","@id":"https:\/\/euthanasiasleep.com\/#website","url":"https:\/\/euthanasiasleep.com\/","name":"Eutanasia Sonno","description":"Eutanasia Sonno","publisher":{"@id":"https:\/\/euthanasiasleep.com\/#organization"},"alternateName":"EuthanasiaSleep","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/euthanasiasleep.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/euthanasiasleep.com\/#organization","name":"Eutanasia Sonno","alternateName":"EuthanasiaSleep","url":"https:\/\/euthanasiasleep.com\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/euthanasiasleep.com\/#\/schema\/logo\/image\/","url":"https:\/\/euthanasiasleep.com\/wp-content\/uploads\/2025\/03\/kisspng-health-care-public-health-medicine-hospital-cupped-hands-5b5bed5c4cf652.0198420915327511963153.jpg","contentUrl":"https:\/\/euthanasiasleep.com\/wp-content\/uploads\/2025\/03\/kisspng-health-care-public-health-medicine-hospital-cupped-hands-5b5bed5c4cf652.0198420915327511963153.jpg","width":900,"height":800,"caption":"Euthanasia Sleep"},"image":{"@id":"https:\/\/euthanasiasleep.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/euthanasiasleep.com\/it\/wp-json\/wp\/v2\/product\/174","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/euthanasiasleep.com\/it\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/euthanasiasleep.com\/it\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/euthanasiasleep.com\/it\/wp-json\/wp\/v2\/comments?post=174"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/euthanasiasleep.com\/it\/wp-json\/wp\/v2\/media\/214"}],"wp:attachment":[{"href":"https:\/\/euthanasiasleep.com\/it\/wp-json\/wp\/v2\/media?parent=174"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/euthanasiasleep.com\/it\/wp-json\/wp\/v2\/product_brand?post=174"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/euthanasiasleep.com\/it\/wp-json\/wp\/v2\/product_cat?post=174"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/euthanasiasleep.com\/it\/wp-json\/wp\/v2\/product_tag?post=174"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}